Special Considerations in the Management of HIV-Infected Patients From Minority Communities

  • Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
  • Section Editor: Judith S. Currier, MD, MSc
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/9/18 (What's New)

Summary

  • REALMRK trial was a single-arm study evaluating raltegravir in treatment-naive and -experienced patients, of whom 56% were black[Squires 2013b]
  • Response rates were similar for black and nonblack patients
  • Clinical adverse events considered drug related occurred in 14% of blacks and 9% of nonblacks

Action required

Keywords: Initial Antiretroviral Therapy, Minority-Ethnic Communities, Pharmacokinetics, Special Populations

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.